AppLovin
APP
$266.13
-4.71%
AppLovin is a vertically integrated advertising technology company that operates a demand-side platform (AppDiscovery, roughly 80% of revenue), a supply-side platform (Max), and an exchange connecting advertisers and mobile app publishers, with its Axon 2 machine-learning engine serving as the core growth driver. The company has evolved from a mobile gaming-adjacent ad network into a high-margin, AI-native performance advertising platform, positioning itself as a direct challenger to Meta and Google in mobile app monetization while running an exceptionally lean operation of fewer than 900 employees. The investor narrative has shifted dramatically in 2026: after a multi-year re-rating driven by Axon 2 efficiency gains and explosive margin expansion, the stock has de-rated sharply on fears of competitive encroachment from Meta's Advantage+ and AI-driven ad automation, a BofA downgrade to Neutral in August, and a broader skepticism about whether AppLovin's outsized growth and ~88% gross margins are durable. Bulls point to a Rule-of-40 score rivaling Palantir's at a far cheaper multiple and aggressive buybacks, while bears argue the decelerating price action reflects a maturing growth algorithm and rising platform risk.…
APP
AppLovin
$266.13
Related headlines
APP 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AppLovin's 12-month outlook, with a consensus price target around $480.08 and implied upside of +80.4% versus the current price.
Average Target
$480.08
0 analysts
Implied Upside
+80.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$325 - $790
Analyst target range
Coverage is deep with 31 analysts, and the consensus recommendation is Buy with a mean rating of 1.576 (where 1.0 is a Strong Buy). The average target price of $480.08 implies +80.4% upside from the current $266.13, a gap that signals the sell-side believes the drawdown is overdone even as the stock trades near its 52-week low. Sentiment leans clearly bullish, but the persistence of Buy ratings through a 56% decline raises questions about whether estimates are stale relative to the market's repricing.
The target range is extraordinarily wide — $325 low to $790 high, a 143% spread — signaling high uncertainty and low conviction in point estimates. The high target of $790 implies multiple expansion back toward prior peak valuations and sustained 50%+ growth with Axon 2 competitive durability, while the low target of $325 still represents +22% upside and prices in margin compression and competitive share loss without a full bear case. Institutional ratings show a notable crack: BofA downgraded from Buy to Neutral on August 11, 2026, while Morgan Stanley, BTIG, Evercore, Needham, and Benchmark maintained Buy/Overweight and Piper Sandler and Wells Fargo stayed Neutral — a pattern of stable-to-slightly-deteriorating sentiment where the consensus has not yet caught down to price. The wide dispersion and recent downgrade suggest the market is voting with price while analysts lag, and the gap between the $480 average target and the $266 price is the key tension for investors to resolve.
Drowning in data?
Find the real signal!
Bulls vs Bears: APP Investment Factors
The bear case currently has stronger near-term evidence: price action is in capitulation mode near the 52-week low with accelerating negative momentum and a fresh BofA downgrade, and the market is clearly voting against the forward estimates. The bull case rests on fundamentals that remain genuinely exceptional — 52.8% revenue growth, 88.3% gross margins, $4.5B TTM free cash flow, and a 12.97x forward PE — which makes this a pure multiple-compression event rather than a deterioration story. The single most important tension is whether the forward EPS of $29.78 is achievable: if Axon 2 sustains 50%+ growth, the stock is dramatically undervalued; if Meta's Advantage+ erodes the algorithm's edge, the forward multiple is a value trap. Until the stock confirms a base above $260.59, the technical evidence favors patience over catching the falling knife.
Bullish
- Hyper-growth at a single-digit forward multiple: Q2 2026 revenue of $1.924B grew 52.82% YoY, yet the stock trades at a forward PE of just 12.97x versus a trailing PE of 68.5x. Consensus forward EPS of $29.78 implies earnings roughly quintupling, and a PEG of 0.62 suggests the market is pricing almost no value for that growth.
- Elite margins with operating leverage: Gross margin of 88.26%, operating margin of 77.68%, and EBITDA margin of 80.9% ($1.557B EBITDA on $1.924B revenue) are extraordinary even by software standards. Net margin expanded from 49.7% in Q1 2025 to 65.8% in Q2 2026, showing margins are widening, not compressing.
- Massive analyst upside and Buy consensus: 31 analysts carry a Buy consensus (mean rating 1.576) with an average target of $480.08, implying +80.4% upside from $266.13. Even the lowest target of $325 still implies +22% upside, meaning the sell-side sees the drawdown as overdone.
- Strong cash generation funding buybacks: TTM free cash flow is $4.499B with $3.053B cash on hand and a current ratio of 3.32. The company repurchased $551M of stock in Q2 2026 and $982M in Q1, funded entirely by internal cash flow, shrinking the share count to ~336.6M.
Bearish
- Severe downtrend near 52-week low: The stock is down 56.06% over one year and 56.96% YTD, sitting just 2.1% above its 52-week low of $260.59 and 63.9% below its high of $738.01. A decisive break below $260.59 would open a vacuum with no historical floor.
- Accelerating negative momentum: The 1-month decline of 18.51% is steeper than the 3-month decline of 37.31%, signaling worsening selling pressure rather than stabilization. Relative strength of -19.73 (1M) and -40.00 (3M) versus the S&P shows the stock is being sold even as the tape rises.
- Forward estimates embed enormous execution risk: The 68.5x trailing versus 12.97x forward PE gap requires earnings to roughly quintuple to consensus EPS of $29.78. If Axon 2 growth decelerates or Meta's Advantage+ takes share, those estimates get cut and the 'cheap' forward multiple evaporates.
- Analyst sentiment lagging price action: BofA downgraded to Neutral on August 11, 2026, and the target range of $325-$790 is a 143% spread, signaling low conviction. The persistence of Buy ratings through a 56% decline raises the risk that estimates are stale relative to the market's repricing.
APP Technical Analysis
AppLovin is in a severe, sustained downtrend, with the stock down 56.06% over the past year and 56.96% year-to-date, dramatically underperforming the S&P 500's +15.53% and +11.93% respective returns. At a current price of $266.13, the stock sits just 2.1% above its 52-week low of $260.59 and a staggering 63.9% below its 52-week high of $738.01, placing it at roughly 1.1% of its 52-week range — a positioning that signals capitulation-style selling rather than a healthy pullback, and one that historically demands confirmation of a base before value buyers step in. The max drawdown of -64.26% underscores how violently the market has repriced the growth narrative.
Short-term momentum is unambiguously negative and accelerating to the downside: the stock is down 18.51% over the past month and 37.31% over three months, meaning the 1-month decline is steeper than the 3-month decline, a pattern of worsening selling pressure rather than stabilization. This deceleration diverges sharply from the longer-term trend only in magnitude — both timeframes are negative — but the relative strength readings are damning, with 1-month relative strength of -19.73 and 3-month relative strength of -40.00 versus the S&P, indicating the stock is being sold regardless of a rising tape. The most recent session alone saw a -4.71% drop on 3.51 million shares, and the failure to hold the $280 area in mid-October suggests sellers remain in control; RSI is not provided but the price structure implies deeply oversold conditions that have yet to produce a durable bounce.
Key technical levels are stark: support rests at the 52-week low of $260.59, just $5.54 below the current price, and a decisive breakdown below that level would likely trigger momentum-driven liquidation and open a vacuum toward lower prices with no obvious historical floor. Resistance is layered far overhead, with the 52-week high of $738.01 representing a 177% gap and intermediate supply likely clustered around the $300-$335 region where the stock consolidated in August and September before breaking down. With a beta of 2.557, AppLovin is roughly 2.6x as volatile as the market, meaning position sizing must be dramatically reduced relative to a market-weight holding and stop-loss discipline is paramount — a 10% market move implies a ~26% move here, which cuts both ways in a name already trading near its lows.
Beta
2.56
2.56x market volatility
Max Drawdown
-64.3%
Largest decline past year
52-Week Range
$261-$738
Price range past year
Annual Return
-56.1%
Cumulative gain past year
| Period | APP Return | S&P 500 |
|---|---|---|
| 1m | -18.5% | +0.2% |
| 3m | -37.3% | +2.9% |
| 6m | -44.2% | +8.4% |
| 1y | -56.1% | +14.9% |
| ytd | -57.0% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APP Fundamental Analysis
Revenue growth remains exceptional even as the stock collapses: Q2 2026 revenue of $1.924 billion grew 52.82% year-over-year, building on a clear multi-quarter acceleration from $1.159 billion in Q1 2025, $1.259 billion in Q2 2025, $1.405 billion in Q3 2025, $1.658 billion in Q4 2025, and $1.842 billion in Q1 2026. Sequential growth has been remarkably consistent — roughly +8.6% in Q1 2026 and +4.4% in Q2 2026 — and the company operates as a single reportable segment, meaning the DSP (AppDiscovery) remains the engine while the Max SSP provides supply-side leverage. The trajectory implies a business still compounding at hyper-growth rates, which makes the 56% stock decline a pure multiple-compression event rather than a fundamental deterioration story, though the decelerating sequential cadence bears watching.
Profitability is elite: Q2 2026 net income of $1.267 billion produced a 65.8% net margin, while gross margin of 88.26% and operating margin of 77.68% are extraordinary even by software standards and reflect the operating leverage of Axon 2. Margins have been stable to expanding — gross margin moved from 86.91% in Q1 2025 to 88.26% in Q2 2026, and net margin rose from 49.7% to 65.8% over the same span — with EBITDA of $1.557 billion in Q2 2026 representing an 80.9% EBITDA margin. The company is not merely profitable but among the most profitable at scale in ad tech, and the consistency of ~65% net margins across the last four quarters argues against margin compression being the near-term risk.
Balance sheet and cash generation are strong but not pristine: free cash flow TTM stands at $4.499 billion, Q2 2026 operating cash flow was $869 million (down from $1.291 billion in Q1 due to working capital swings), and cash on hand reached $3.053 billion against a current ratio of 3.32. Debt-to-equity of 1.66 is moderate and interest coverage is robust at roughly 29x, while ROE of 156.2% and ROA of 46.5% reflect both genuine profitability and a leveraged, buyback-shrunk equity base. The company is aggressively returning capital — $551 million of stock repurchased in Q2 2026 and $982 million in Q1 — funded entirely by internal cash flow, but the elevated PCF of 57.5x and EV/EBITDA of 52.7x mean the market is still paying dearly for that cash generation despite the drawdown.
Quarterly Revenue
$1.9B
2026-06
Revenue YoY Growth
+52.8%
YoY Comparison
Gross Margin
88.3%
Latest Quarter
Free Cash Flow
$4.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APP Overvalued?
Because AppLovin is solidly profitable (Q2 2026 net income of $1.267 billion), the PE ratio is the appropriate primary metric, and the picture is bifurcated: trailing PE of 68.5x versus forward PE of just 12.97x. That enormous gap implies the market expects earnings to roughly quintuple, consistent with consensus EPS estimates of $29.78 for the forward period versus the trailing figure — a gap that, if delivered, would make the stock optically cheap, but one that also embeds enormous execution risk and explains why the multiple has compressed so violently as confidence in that growth path has eroded.
On peer comparison, the stock's headline multiples look extreme: PS of 41.7x, EV/Sales of 13.75x, and PB of 106.9x, though the forward PE of 12.97x is actually below the broader software industry average, creating a stark contradiction between trailing and forward optics. The PEG ratio of 0.62 suggests the stock is cheap relative to its expected growth rate, and the Rule-of-40 comparison to Palantir in recent coverage reinforces that AppLovin trades at a fraction of high-growth software peers on a growth-adjusted basis. The premium on sales and book metrics is a function of the tiny equity base and buybacks rather than operational overvaluation, but the market is clearly unwilling to underwrite the forward estimates at face value.
Historically, AppLovin's valuation has collapsed from its peak: PS ratio has fallen from 173.1x in Q3 2025 to 41.7x today, and PE from 72.7x to 68.5x trailing (with the forward multiple at 12.97x), placing the stock near the bottom of its own multi-year valuation band. PB has fallen from 165.0x in Q3 2025 to 106.9x, and the enterprise value multiple has compressed from 221.3x to 52.7x — a dramatic de-rating that suggests either a genuine value opportunity if growth holds, or that the market is pricing in fundamental deterioration and competitive share loss to Meta. The forward PE of 12.97x against a 52.8% revenue growth rate is the single most important data point in the valuation debate.
PE
68.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 20x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
52.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the dependence on continued hyper-growth to justify the forward valuation. The 12.97x forward PE only looks cheap if earnings roughly quintuple to the $29.78 consensus EPS, meaning any deceleration in Axon 2's algorithm efficiency would force estimate cuts and re-rate the stock. Sequential revenue growth has already slowed from +8.6% in Q1 2026 to +4.4% in Q2 2026, and roughly 80% of revenue comes from the single AppDiscovery DSP, creating concentration risk. Debt-to-equity of 1.66 is moderate with ~29x interest coverage, but ROE of 156.2% is inflated by a buyback-shrunk equity base, and Q2 operating cash flow fell to $869M from $1.291B in Q1 on working capital swings.
Market and competitive risks are dominated by Meta's Advantage+ and AI-driven ad automation encroaching on AppLovin's performance-advertising turf, the core thesis behind the de-rating. The stock's beta of 2.557 makes it roughly 2.6x as volatile as the market, so a 10% market drawdown implies a ~26% hit here, and sector rotation away from high-multiple ad tech would compound the pain. Valuation compression is already severe — PS fell from 173.1x to 41.7x and EV/EBITDA from 221.3x to 52.7x — but headline multiples of 41.7x sales and 106.9x book still leave room for further contraction if growth confidence erodes. The BofA downgrade to Neutral on August 11, 2026, and the 143% analyst target spread ($325-$790) signal that conviction is fracturing.
The worst-case scenario is a chain in which Q3 2026 results show revenue growth decelerating below 40% and management guides down, triggering a wave of estimate cuts that collapses the forward EPS story and forces the stock through the $260.59 52-week low. With no historical floor below that level, momentum-driven liquidation could extend toward the $200-$230 region, implying a further -15% to -25% from the current $266.13. The realized max drawdown of -64.26% already demonstrates the magnitude of damage this name can inflict, and a full bear case to the analyst low of $325 is actually above the current price — meaning the downside is defined by technical levels, not analyst targets, and could realistically reach -25% to -35% to the $175-$200 zone if the growth algorithm is deemed structurally impaired.